User login
Key clinical point: Serum levels of IL-6 and IL-10 at diagnosis may serve as predictors of treatment response and prognosis in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL).
Major finding: Patients with partial or no rresponse vs complete response to treatment had significantly higher serum IL-6 (P = .009) and IL-10 (P < .001) levels. High serum IL-6 (≥ 4.5 pg/mL) and IL-10 (≥ 5.0 pg/mL) levels were independent prognostic factors for relapse (adjusted hazard ratio [aHR] 2.524; P = .003, and aHR 1.835; P = .007, respectively) and survival (aHR 2.012; P = .031, and aHR 5.312; P = .017, respectively).
Study details: This single-center retrospective study included 77 patients with newly diagnosed DLBCL and 77 matched control individuals without DLBCL.
Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.
Source: Bao C et al. Cytokine profiles in patients with newly diagnosed diffuse large B-cell lymphoma: IL-6 and IL-10 levels are associated with adverse clinical features and poor outcomes. Cytokine. 2023;169:156289 (Jul 13). doi: 10.1016/j.cyto.2023.156289
Key clinical point: Serum levels of IL-6 and IL-10 at diagnosis may serve as predictors of treatment response and prognosis in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL).
Major finding: Patients with partial or no rresponse vs complete response to treatment had significantly higher serum IL-6 (P = .009) and IL-10 (P < .001) levels. High serum IL-6 (≥ 4.5 pg/mL) and IL-10 (≥ 5.0 pg/mL) levels were independent prognostic factors for relapse (adjusted hazard ratio [aHR] 2.524; P = .003, and aHR 1.835; P = .007, respectively) and survival (aHR 2.012; P = .031, and aHR 5.312; P = .017, respectively).
Study details: This single-center retrospective study included 77 patients with newly diagnosed DLBCL and 77 matched control individuals without DLBCL.
Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.
Source: Bao C et al. Cytokine profiles in patients with newly diagnosed diffuse large B-cell lymphoma: IL-6 and IL-10 levels are associated with adverse clinical features and poor outcomes. Cytokine. 2023;169:156289 (Jul 13). doi: 10.1016/j.cyto.2023.156289
Key clinical point: Serum levels of IL-6 and IL-10 at diagnosis may serve as predictors of treatment response and prognosis in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL).
Major finding: Patients with partial or no rresponse vs complete response to treatment had significantly higher serum IL-6 (P = .009) and IL-10 (P < .001) levels. High serum IL-6 (≥ 4.5 pg/mL) and IL-10 (≥ 5.0 pg/mL) levels were independent prognostic factors for relapse (adjusted hazard ratio [aHR] 2.524; P = .003, and aHR 1.835; P = .007, respectively) and survival (aHR 2.012; P = .031, and aHR 5.312; P = .017, respectively).
Study details: This single-center retrospective study included 77 patients with newly diagnosed DLBCL and 77 matched control individuals without DLBCL.
Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.
Source: Bao C et al. Cytokine profiles in patients with newly diagnosed diffuse large B-cell lymphoma: IL-6 and IL-10 levels are associated with adverse clinical features and poor outcomes. Cytokine. 2023;169:156289 (Jul 13). doi: 10.1016/j.cyto.2023.156289